205 related articles for article (PubMed ID: 25902842)
21. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
Muenzer J; Hendriksz CJ; Fan Z; Vijayaraghavan S; Perry V; Santra S; Solanki GA; Mascelli MA; Pan L; Wang N; Sciarappa K; Barbier AJ
Genet Med; 2016 Jan; 18(1):73-81. PubMed ID: 25834948
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients.
Giugliani R; Harmatz P; Jones SA; Mendelsohn NJ; Vellodi A; Qiu Y; Hendriksz CJ; Vijayaraghavan S; Whiteman DA; Pano A
Mol Genet Metab Rep; 2017 Sep; 12():2-7. PubMed ID: 28243577
[TBL] [Abstract][Full Text] [Related]
23. Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18630351
[TBL] [Abstract][Full Text] [Related]
24. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.
Muenzer J; Beck M; Giugliani R; Suzuki Y; Tylki-Szymanska A; Valayannopoulos V; Vellodi A; Wraith JE
Genet Med; 2011 Feb; 13(2):102-9. PubMed ID: 21233716
[TBL] [Abstract][Full Text] [Related]
25. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
Marín LL; Gutiérrez-Solana LG; Fernández AT
Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
[TBL] [Abstract][Full Text] [Related]
26. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
[TBL] [Abstract][Full Text] [Related]
27. [Clinical study of enzyme replacement therapy with idursulfase].
Gutiérrez-Solana LG
Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
[TBL] [Abstract][Full Text] [Related]
28. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
Burton BK; Jego V; Mikl J; Jones SA
J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
[TBL] [Abstract][Full Text] [Related]
29. Idursulfase in Hunter syndrome treatment.
Zareba G
Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
[TBL] [Abstract][Full Text] [Related]
30. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
Christianto A; Watanabe H; Nakajima T; Inazu T
Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
[TBL] [Abstract][Full Text] [Related]
31. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome).
Serrano CD; Gomez JF
J Investig Allergol Clin Immunol; 2011; 21(7):571-2. PubMed ID: 22312944
[No Abstract] [Full Text] [Related]
32. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT.
Yee KS; Chirila C; Davenport E; Mladsi D; Barnett C; Kronenberger WG
Orphanet J Rare Dis; 2023 Nov; 18(1):343. PubMed ID: 37915038
[TBL] [Abstract][Full Text] [Related]
33. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.
Lampe C; Bosserhoff AK; Burton BK; Giugliani R; de Souza CF; Bittar C; Muschol N; Olson R; Mendelsohn NJ
J Inherit Metab Dis; 2014 Sep; 37(5):823-9. PubMed ID: 24596019
[TBL] [Abstract][Full Text] [Related]
34. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
Mol Genet Metab; 2022; 137(1-2):127-139. PubMed ID: 36027721
[TBL] [Abstract][Full Text] [Related]
35. Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome.
Julien DC; Woolgar K; Pollard L; Miller H; Desai A; Lindstrom K; Kishnani PS
Front Immunol; 2020; 11():1000. PubMed ID: 32508845
[TBL] [Abstract][Full Text] [Related]
36. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
[TBL] [Abstract][Full Text] [Related]
37. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
Chung JK; Brown E; Crooker B; Palmieri KJ; McCauley TG
PLoS One; 2016; 11(10):e0164765. PubMed ID: 27764180
[TBL] [Abstract][Full Text] [Related]
38. Hunter disease before and during enzyme replacement therapy.
Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
[TBL] [Abstract][Full Text] [Related]
39. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.
Galán-Gómez E; Guerrero-Rico A; Cáceres-Marzal C; Zambrano-Castaño M; Moreno-Tejero ML; Grande-Tejada AM; Fernández-Hernández S; Vaquerizo-Madrid J; Cardesa-García JJ
Eur J Med Genet; 2008; 51(3):268-71. PubMed ID: 18396123
[TBL] [Abstract][Full Text] [Related]
40. Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
Muenzer J; Vijayaraghavan S; Stein M; Kearney S; Wu Y; Alexanderian D
Genet Med; 2022 Jul; 24(7):1437-1448. PubMed ID: 35588317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
